We are a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat patients with chronic metabolic diseases and liver diseases. We are dedicated to delivering novel solutions that provide meaningful clinical benefit, address unmet medical needs and improve patient quality of life.
Our lead candidate, berberine ursodeoxycholate (HTD1801), is an investigational gut-liver anti-inflammatory metabolic modulator being evaluated for the treatment of type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC).